GlassScriptPhysician profile
Michael M Lau
NPI 1366531584
$4,758.41
in general payments reported to CMS, 2019-2025
27 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,376 · 2022: $1,290 · 2023: $798 · 2024: $795 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $846.99 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $737.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $478.27 | 2021-2023 | Farxiga |
| Amgen INC. | $383.50 | 2021-2024 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $323.57 | 2021-2024 | |
| Corcept Therapeutics | $269.55 | 2021-2023 | Korlym |
| Lilly USA, LLC | $261.52 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $213.88 | 2021-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $193.50 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.28 | 2021-2024 | Jardiance |
| Medtronic, INC. | $137.55 | 2021-2023 | Minimed 780g, Minimed 770g |
| Nevro Corp. | $89.65 | 2022 | |
| Janssen Biotech, INC. | $77.18 | 2021 | |
| Xeris Pharmaceuticals, INC. | $76.79 | 2021-2023 | Gvoke Hypopen |
| Abbvie INC. | $72.55 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $67.03 | 2023-2024 | Cologuard Collection Kit |
| Averitas Pharma INC. | $51.67 | 2024 | Qutenza |
| Pfizer INC. | $46.96 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $46.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $46.06 | 2022-2023 | |
| Insulet Corporation | $45.33 | 2021-2023 | Omnipod |
| Daiichi Sankyo INC. | $37.39 | 2021 | |
| Mannkind Corporation | $34.15 | 2021 | |
| Edwards Lifesciences Corporation | $31.95 | 2022 | |
| Gilead Sciences, INC. | $18.05 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.